| P50 | author | Iris Sommer | Q21261367 |
| P2093 | author name string | R S Kahn | |
| P2860 | cites work | Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial | Q21560890 |
| | Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study | Q81245412 |
| | Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis | Q83827811 |
| | Schizophrenia is a cognitive illness: time for a change in focus | Q87218229 |
| | Stereologic investigation of the posterior part of the hippocampus in schizophrenia | Q48934263 |
| | Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 |
| | An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis | Q33860571 |
| | Impact of brief exercise on circulating monocyte gene and microRNA expression: implications for atherosclerotic vascular disease | Q33914350 |
| | 1H-MRS at 4 tesla in minimally treated early schizophrenia | Q33941381 |
| | The course of brain abnormalities in schizophrenia: can we slow the progression? | Q33951370 |
| | Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies | Q33957510 |
| | Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia | Q34048560 |
| | Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia | Q34142112 |
| | Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? | Q34194961 |
| | Cognitive functioning in prodromal psychosis: a meta-analysis | Q34278910 |
| | Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. | Q34295212 |
| | Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encepha | Q34323973 |
| | Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. | Q34330678 |
| | Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. | Q34337272 |
| | Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. | Q34424470 |
| | Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset | Q34496393 |
| | D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia | Q34528409 |
| | De novo mutations in schizophrenia implicate synaptic networks | Q34540372 |
| | Neuroimaging findings in the at-risk mental state: a review of recent literature | Q34552937 |
| | A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia | Q34579324 |
| | Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial | Q34616402 |
| | Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk | Q34636460 |
| | Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis | Q35158156 |
| | Major histocompatibility complex I in brain development and schizophrenia | Q35163148 |
| | Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features | Q35740484 |
| | 18F-fallypride binding potential in patients with schizophrenia compared to healthy controls | Q35752862 |
| | Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes | Q36170457 |
| | NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia | Q36339850 |
| | Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission | Q36633620 |
| | Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task | Q36636329 |
| | NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia | Q36718684 |
| | Extended remediation of sleep deprived-induced working memory deficits using fMRI-guided transcranial magnetic stimulation | Q36831263 |
| | Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. | Q36871782 |
| | Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses | Q36916561 |
| | Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study | Q45001453 |
| | Effects of birth insult and stress at adulthood on excitatory amino acid receptors in adult rat brain | Q45081925 |
| | Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. | Q45226292 |
| | Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study | Q45242209 |
| | Quantitative study of gliosis in schizophrenia and Huntington's chorea | Q45299045 |
| | Nitric oxide and symptom reduction in schizophrenia | Q45777394 |
| | Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? | Q45897333 |
| | Changes in cortical thickness during the course of illness in schizophrenia. | Q45927962 |
| | Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. | Q45950519 |
| | Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. | Q45999628 |
| | Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. | Q46030016 |
| | A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia | Q46099117 |
| | Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation | Q46119208 |
| | A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders | Q46158571 |
| | Elevated striatal dopamine function linked to prodromal signs of schizophrenia | Q46174418 |
| | Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. | Q46214272 |
| | Schizophrenia and the brain: a prospective clinico-neuropathological study | Q46316433 |
| | Attachment: developmental pathways to affective dysregulation in young people at ultra-high risk of developing psychosis | Q46325512 |
| | Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia | Q46421438 |
| | Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism | Q46437594 |
| | Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. | Q46660768 |
| | Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial | Q46675364 |
| | The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. | Q46705987 |
| | Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia | Q46772594 |
| | Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients | Q46801461 |
| | Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases | Q46847222 |
| | Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patients. | Q46847750 |
| | Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning | Q46853129 |
| | Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia | Q46974035 |
| | Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia | Q47820010 |
| | Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia | Q48090415 |
| | Intracranial volume change in craniosynostosis | Q48100527 |
| | Evidence for activation of microglia in patients with psychiatric illnesses | Q48118772 |
| | Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. | Q48121459 |
| | Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. | Q48133694 |
| | White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment | Q48148097 |
| | Is there gliosis in schizophrenia? Investigation of the temporal lobe | Q48178516 |
| | Markers of inflammation in the prefrontal cortex of individuals with schizophrenia | Q48197455 |
| | Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia | Q48283671 |
| | Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide | Q48335595 |
| | Dopamine synthesis capacity in patients with treatment-resistant schizophrenia | Q48350915 |
| | Facilitation of performance in a working memory task with rTMS stimulation of the precuneus: frequency- and time-dependent effects | Q48365867 |
| | Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography | Q48374750 |
| | Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis | Q48394255 |
| | Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait | Q48405049 |
| | Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. | Q48407980 |
| | Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study". | Q48430338 |
| | Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. | Q48431127 |
| | The Brain Stem in Psychosis | Q48463208 |
| | Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicity | Q48492190 |
| | Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization | Q48493449 |
| | Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia | Q48506663 |
| | Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis | Q48509996 |
| | The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjects | Q48549692 |
| | Altered white matter connectivity in never-medicated patients with schizophrenia | Q48591458 |
| | Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender | Q48597393 |
| | Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy | Q48614993 |
| | Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. | Q48629131 |
| | Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. | Q48806711 |
| | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| | Rethinking schizophrenia | Q22251086 |
| | Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia | Q24293245 |
| | GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression | Q24610466 |
| | Common variants conferring risk of schizophrenia | Q24614376 |
| | Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies | Q24626182 |
| | Maternal immune activation alters fetal brain development through interleukin-6. | Q24653759 |
| | Functional requirement for class I MHC in CNS development and plasticity | Q24669537 |
| | Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study | Q28238182 |
| | Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 |
| | Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia | Q28248687 |
| | Imaging brain development: the adolescent brain | Q28255668 |
| | Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients | Q28257370 |
| | Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? | Q28279719 |
| | The promise of N-acetylcysteine in neuropsychiatry | Q28284644 |
| | The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production | Q28293593 |
| | Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update | Q28299995 |
| | Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 |
| | Cortical inhibitory neurons and schizophrenia | Q29547683 |
| | Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 |
| | Neurocognitive performance and functional disability in the psychosis prodrome. | Q30353505 |
| | Inflammation and the two-hit hypothesis of schizophrenia | Q30422062 |
| | Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis | Q30450082 |
| | Is the acute NMDA receptor hypofunction a valid model of schizophrenia? | Q30459655 |
| | Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. | Q30471857 |
| | Confounders of excessive brain volume loss in schizophrenia | Q30570024 |
| | A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. | Q30577998 |
| | Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review | Q30592331 |
| | Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies | Q31043017 |
| | What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia | Q31147040 |
| | Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. | Q31861860 |
| | Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia | Q33404028 |
| | White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis | Q33587494 |
| | Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia | Q38414491 |
| | Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study | Q38435398 |
| | Increased prefrontal cortical D₁ receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112. | Q39991406 |
| | The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study | Q40029733 |
| | A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis | Q40095532 |
| | Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro | Q40158583 |
| | Neuropathology of schizophrenia | Q40344568 |
| | Gliosis in schizophrenia: a survey | Q41875189 |
| | MHC class I: an unexpected role in neuronal plasticity | Q42115670 |
| | Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. | Q42519170 |
| | The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. | Q42623258 |
| | Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study | Q42984373 |
| | Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. | Q43115816 |
| | Hippocampal plasticity in response to exercise in schizophrenia | Q43177651 |
| | GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study | Q43214682 |
| | NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex | Q43238242 |
| | Neuroinflammation in schizophrenia-related psychosis: a PET study. | Q43259552 |
| | Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study | Q43277678 |
| | Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. | Q43291248 |
| | Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia | Q43444866 |
| | Effects of aerobic interval training on metabolic complications and cardiorespiratory fitness in young adults with psychotic disorders: a pilot study | Q43628737 |
| | Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. | Q43653441 |
| | Exercise therapy, cardiorespiratory fitness and their effect on brain volumes: a randomised controlled trial in patients with schizophrenia and healthy controls | Q43654315 |
| | Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? | Q43703403 |
| | Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study | Q43851337 |
| | Prefrontal dopamine D1 receptors and working memory in schizophrenia. | Q43972774 |
| | PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia | Q43977652 |
| | Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study | Q43987270 |
| | Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia | Q44045578 |
| | Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. | Q44066171 |
| | Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers | Q44201512 |
| | Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients | Q44568973 |
| | Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. | Q44646513 |
| | Determining optimal rTMS parameters through changes in cortical inhibition | Q44647924 |
| | Dopamine transporter change in drug-naı̈ve schizophrenia: an imaging study with 99mTc-TRODAT-1 | Q44659275 |
| | Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. | Q44783995 |
| | Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis | Q44827836 |
| | Regulation of N-methyl-D-aspartate receptor subunit expression in the fetal guinea pig brain | Q44872269 |
| | Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia | Q44915190 |
| | 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia | Q44915208 |
| | Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. | Q50703929 |
| | Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. | Q50735793 |
| | Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome. | Q50740954 |
| | Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. | Q50803831 |
| | Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. | Q51032268 |
| | C-reactive protein is elevated in schizophrenia. | Q51290721 |
| | Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise. | Q51331215 |
| | Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. | Q51418888 |
| | Sites of antagonist action on N-methyl-D-aspartic acid receptors studied using fluctuation analysis and a rapid perfusion technique. | Q51769623 |
| | Gliosis in schizophrenia. | Q52068982 |
| | School performance as a premorbid marker for schizophrenia: a twin study. | Q52107806 |
| | Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. | Q52217996 |
| | Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. | Q52506986 |
| | Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. | Q53233780 |
| | Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. | Q53411974 |
| | [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone] | Q53534576 |
| | Schizophrenia as a progressive brain disease | Q60610023 |
| | Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study | Q60641038 |
| | Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study | Q60641039 |
| | Efficacy of N-Acetylcysteine in the Treatment of Nicotine Dependence: A Double-Blind Placebo-Controlled Pilot Study | Q63361711 |
| | A histological study of the corpus callosum in chronic schizophrenia | Q70909659 |
| | An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients | Q71823136 |
| | Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics | Q73629060 |
| | Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics | Q74315852 |
| | S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study | Q79831226 |
| | C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia | Q80301115 |
| | Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics | Q80982125 |
| | Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study | Q36928703 |
| | Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning | Q36948917 |
| | Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review | Q37001984 |
| | PRENATAL INFECTION, MATERNAL IMMUNE ACTIVATION, AND RISK FOR SCHIZOPHRENIA. | Q37097440 |
| | In vivo measurements of glutamate, GABA, and NAAG in schizophrenia | Q37131013 |
| | Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects | Q37131066 |
| | Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia | Q37135649 |
| | Psychological need satisfaction, intrinsic motivation and affective response to exercise in adolescents | Q37140734 |
| | Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study | Q37215695 |
| | RETRACTED: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients | Q37267763 |
| | Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia | Q37364399 |
| | Neural basis of psychosis-related behaviour in the infection model of schizophrenia | Q37372894 |
| | Molecular profiles of schizophrenia in the CNS at different stages of illness. | Q37439158 |
| | Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis | Q37451389 |
| | White matter integrity as a predictor of response to treatment in first episode psychosis | Q37477310 |
| | Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. | Q37541981 |
| | The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline | Q37784829 |
| | First-episode schizophrenia | Q37818030 |
| | Glutamate and psychosis risk | Q37975268 |
| | Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults | Q37984014 |
| | White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies | Q38073848 |
| | Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis | Q38122854 |
| | Inflammatory cytokine network in schizophrenia | Q38138169 |
| | The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episode. | Q38140161 |
| | Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis | Q38160514 |
| | Dopaminergic basis of salience dysregulation in psychosis | Q38175606 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antipsychotics | Q208144 |
| | schizophrenia | Q41112 |
| P304 | page(s) | 84-97 | |
| P577 | publication date | 2014-07-22 | |
| | 2015-02-01 | |
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | The neurobiology and treatment of first-episode schizophrenia | |
| P478 | volume | 20 | |